|Min SIP Amount||₹500|
|NAV||₹144.60 (13 Apr 2021)|
|Fund Started||27 May 1999|
|Fund Size||₹618 Cr|
|Aurobindo Pharma Ltd.||Healthcare||Equity||9.6%|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||9.5%|
|Dr. Reddy's Laboratories Ltd.||Healthcare||Equity||8.4%|
|Divi's Laboratories Ltd.||Healthcare||Equity||6.2%|
|Eris Lifesciences Ltd||Healthcare||Equity||5.7%|
|Cadila Healthcare Ltd.||Healthcare||Equity||5.4%|
|Fortis Healthcare Ltd.||Healthcare||Equity||4.4%|
|Ajanta Pharma Ltd.||Healthcare||Equity||4.1%|
|JB Chemicals & Pharmaceuticals Ltd.||Healthcare||Equity||3.6%|
UTI Healthcare Fund Regular Plan Growth is a Equity Mutual Fund Scheme launched by UTI Mutual Fund. This scheme was made available to investors on 27 May 1999. V Srivatsa, Ritesh Rathod is the Current Fund Manager of UTI Healthcare Fund Regular Plan Growth fund.The fund currently has an Asset Under Management(AUM) of ₹618 Cr and the Latest NAV as of 13 Apr 2021 is ₹144.60.
The UTI Healthcare Fund Regular Plan Growth is rated Very High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 30 days.
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.